Our Team: Driven & Diverse

Just as we bring together two modalities in our bifunctional therapies, our work also bridges two continents with a team in Cambridge, Mass. and a dedicated research arm, supported by Biocon, in Bangalore, India. Together we are working towards a shared vision to provide first-in-class, meaningful therapies to cancer patients.


Our experienced leadership and clinical development team in Cambridge has deep relationships with the world’s top cancer centers and extensive experience in company-building and drug development.


The Bangalore group, a dedicated research arm supported by Biocon, is comprised of skilled protein engineers, immunologists and CMC experts who have experience building highly complex molecules and a track record of developing FDA-approved drugs.


Claire Mazumdar, Ph.D., MBA

Chief Executive Officer

Ryan Cohlhepp, Pharm.D.

President & Chief Operating Officer

Ivan Hyep, MBA

Chief Financial Officer

Liviu Niculescu, M.D.

Chief Medical Officer

Seng-Lai (Thomas) Tan, Ph.D.

Senior Scientific Advisor

Amy Lynch

Head of Operations & HR

Rachel Salazar, D.H.Sc.

Head of Program and Portfolio Management

David Bohr, MBA, MS

Head of Clinical Operations

Board of Directors

Ryan Cohlhepp, Pharm.D.

Board Director
Bicara Therapeutics

F. Stephen Hodi, M.D.

Board Director, Chairman of the Clinical Advisory Board
Harvard Medical School

Vijay Kuchroo, D.V.M., Ph.D.

Chairman of the Board
Harvard Medical School

Nils Lonberg, Ph.D.

Board Director
Canaan Partners

Claire Mazumdar, Ph.D., MBA

Board Director
Bicara Therapeutics

Kiran Mazumdar-Shaw

Board Director
Biocon, Ltd.

Scientific Advisory Board

Chaitanya Divgi, MBBS

CEO of Divgi Consulting

Thomas F. Gajewski, M.D., Ph.D.

University of Chicago

Caetano Reis e Sousa, D.Phil

The Francis Crick Institute

Arlene Sharpe, M.D., Ph.D.

Harvard Medical School

Dario Vignali, Ph.D.

University of Pittsburgh School of Medicine

Jedd D. Wolchok, M.D., Ph.D., FASCO

Memorial Sloan Kettering Cancer Center


We are proud to draw our seed funding from Biocon, a global biopharmaceutical company changing patients’ lives in more than 120 countries by finding new and affordable ways to treat diabetes, cancer and autoimmune diseases. Biocon has been advancing biotechnology for more than 40 years and is comprised of a talented and dedicated workforce of more than 12,000 employees.